---
title: "HBM Holdings Expects 2025 Profit to Surge to Up to US$95 Million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274729588.md"
datetime: "2026-02-04T00:00:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274729588.md)
  - [en](https://longbridge.com/en/news/274729588.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274729588.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274729588.md) | [繁體中文](https://longbridge.com/zh-HK/news/274729588.md)


# HBM Holdings Expects 2025 Profit to Surge to Up to US$95 Million

HBM Holdings Ltd. has announced a significant increase in its expected profit for the year ended 31 December 2025. Based on preliminary unaudited management accounts, the company anticipates its profit to be in the range of approximately US$88 million to US$95 million, a sharp rise compared to a profit of about US$2.7 million recorded for the previous year. Additionally, total adjusted profit is projected to be between US$91 million and US$98 million, highlighting a substantial improvement in the company’s business performance for the period. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260204-12012725), on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [ProShares UltraShort Nasdaq Biotech (BIS.US)](https://longbridge.com/en/quote/BIS.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

- [Cloudbreak Pharma's 2025 Loss Narrows](https://longbridge.com/en/news/281317115.md)
- [Iterum Therapeutics Received Notice of Delisting](https://longbridge.com/en/news/281174211.md)
- [Stocks in Play: Ventripoint Diagnostics Ltd](https://longbridge.com/en/news/281544776.md)
- [Telomir submits IND for Telomir-1 to treat advanced and metastatic TNBC](https://longbridge.com/en/news/281174396.md)
- [BUZZ-Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug](https://longbridge.com/en/news/281517197.md)